Analyst consensus rating
Phathom Pharmaceuticals Analyst Rating: Strong Buy
Direct answer
Phathom Pharmaceuticals's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.09.
Forecast evidence checked October 19, 2026.
Get free Phathom Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.92
- Average price target
- $20.09
- High price target
- $29.00
- Low price target
- $10.00
- Low target gap
- +44.5%
- Target upside
- +190.3%
- High target gap
- +319.1%
- Target range width
- 274.6%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Phathom Pharmaceuticals?
Phathom Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $20.09.
How far are Phathom Pharmaceuticals's low and high targets from the recorded price?
The low target implies +44.5%, while the high target implies +319.1%.
How many analysts are included in Phathom Pharmaceuticals's consensus?
The verified consensus includes 11 analysts.
How is Phathom Pharmaceuticals's target upside or downside calculated?
The average target of $20.09 is divided by the recorded price of $6.92, then one is subtracted to produce +190.3%. This does not guarantee a future return.
When was Phathom Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.